Certara's CFO Transition
Certara Announces CFO John Gallagher's Resignation, Reaffirms 2026 Financial Guidance
Certara (NASDAQ: CERT) announced Tuesday that Chief Financial Officer John Gallagher will resign effective July 14, 2026, after roughly three years in the role, according to Benzinga. The drug development software company has launched a search for a permanent replacement and named Senior Vice President of Finance Faiz Mohammed as interim CFO starting July 15.
The announcement came paired with a reaffirmation of the company's full-year 2026 revenue guidance of $395 million to $405 million, a clear signal to investors that the leadership change will not alter Certara's near-term financial outlook, Yahoo Finance reported.
Gallagher Departs After a Turbulent Year for Certara
Gallagher joined Certara in April 2023 and is leaving to "pursue another opportunity," according to the company. He will stay through the close of Q2 2026 to help with the handoff. His exit follows a rough stretch for the stock, which fell roughly 46% year-to-date through mid-May after the company posted a Q1 2026 net loss of $8.8 million — a sharp reversal from a $4.7 million profit in Q1 2025.
The company also flagged a key risk: the recently completed sale of its Regulatory Medical Writing business could make it harder to maintain existing customer and partner relationships in the short term, Yahoo Finance noted.
Faiz Mohammed Steps In With Eight Years of Certara Experience
Mohammed has served as Certara's SVP of Finance and Treasurer since 2018. He brings 25 years of finance experience across public and private equity-backed companies, according to Financial Content. His long tenure inside Certara is seen as a stabilizing factor during the search for a permanent CFO.
Analysts described the transition as "orderly." The company was explicit that Gallagher's departure was not related to any disagreements over financial reporting or accounting — a disclosure that helps limit governance concerns for institutional investors.
Medical Writing Sale Reshapes Certara's Core Business
The CFO change comes weeks after Certara completed the sale of its Regulatory Medical Writing unit to Veristat for up to $135 million — $100 million in cash at close plus a $35 million performance-based earn-out. The deal transferred roughly 220 employees to Veristat. The divested unit had generated $50 million in revenue and $17 million in adjusted EBITDA in 2025.
CEO Jon Resnick called the sale a pivot toward "AI-integrated modeling and simulation across the drug development lifecycle." By shedding the writing business, Certara aims to focus on higher-margin software and analytics products — the core of its model-informed drug development platform.
Government Contract Risk Looms Over 2026 Outlook
Even with guidance reaffirmed at $395 million to $405 million in revenue and an adjusted EBITDA margin of 30% to 32%, Certara flagged notable risks ahead. The company licenses software to the FDA, CDC, and 23 global regulatory agencies. The June 17 filing specifically cited risks from "funding constraints and policy changes" at those agencies, which could trigger contract terminations.
Leerink Partners analyst Michael Cherny kept a Buy rating and an $8.00 price target on the stock just one day before the CFO announcement — a sign of institutional confidence even as retail sentiment has remained bearish. Adjusted diluted EPS guidance for 2026 stands at $0.35 to $0.41, according to Goldea Capital.
Sentiment
NeutralPublishers
4
Articles
2
Reach
4
